GLPwatch
Papers (9189)
Page 91 of 154, ranked by citation count.
- Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
- Optimizing management of glycaemia.
- Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
- Pharmacological treatment of obesity in adults in Norway 2004-2022.
- Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
- Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.
- Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
- <sup>18</sup>F-labeled PEGylated exendin-4 imaging noninvasively differentiates insulinoma from an accessory spleen: the first case report of [18F]FB(ePEG12)12-exendin-4 positron emission tomography/computed tomography for insulinoma.
- Exendin-4 impairs the autophagic flux to induce apoptosis in pancreatic acinar AR42J cells by down-regulating LAMP-2.
- Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.
- The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial.
- Switching from insulin to liraglutide improved glycemic control and the quality of life scores in a case of type 2 diabetes and active Crohn's disease.
- Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus.
- A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
- Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
- Exenatide modulates expression of metalloproteinases and their tissue inhibitors in TNF-α stimulated human retinal pigment epithelial cells.
- Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study.
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
- Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.
- Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers.
- Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.
- EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
- Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on "Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a".
- Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch<sup>®</sup> among self-injection-naïve patients with type 2 diabetes mellitus in Japan.
- Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
- Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
- Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.
- Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
- The pattern of prescribing of glucose modulating agents for type 2 diabetes in general practices in England 2016/17.
- Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
- Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide.
- VMP1-related autophagy induced by a fructose-rich diet in β-cells: its prevention by incretins.
- Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action.
- The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.
- Exendin-4 modifies adipogenesis of human adipose-derived stromal cells isolated from omentum through multiple mechanisms.
- Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats.
- Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin.
- Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide.
- Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials.
- Semaglutide May Ameliorate Fibrosis and Inhibit Epithelial-Mesenchymal Transition in Intrauterine Adhesion Models.
- Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.
- [Exenatide stimulated solute-free water excretion by human kidney].
- Extending our understanding of exenatide: a rare case of angio-oedema.
- The first case of psoriatic skin lesions exacerbation after liraglutide.
- Effect of a GLP-1 mimetic on the insulin response to oral sugar testing in horses.
- Mesolimbic exendin-4 attenuates reward salience evoked by neuropeptide Y and ghrelin.
- Liraglutide treatment counteracts alterations in adipose tissue metabolism induced by orchiectomy in rats.
- Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
- Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
- Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
- Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational "Real-Life" Study.
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
- Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
- GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial.
- Liraglutide promotes angiogenesis in adipose tissue via suppression of adipocyte-derived IL-6.
- The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells.
- Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
- Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice.
- The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion.
- Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis.